Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus HC 1.
ARAZLO vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Unknown
Topical: Apply 0.045% gel once daily to affected areas of the face.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
2–4 hours (terminal); prolonged in renal impairment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid